Publisher
Springer Science and Business Media LLC
Reference56 articles.
1. Jürgensmeier JM, Eder JP, Herbst RS. New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. Clin Cancer Res. 2014;20(17):4425–35.
2. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clinl Oncol. 2018;15(12):731–47.
3. Awad K, Dalby M, Cree I, et al. The precision medicine approach to cancer therapy: part 1 - solid tumours. Pharm J. 2019. https://doi.org/10.1211/PJ.2019.20207119.
4. El-Diery WS, Goldberg RM, Lenz H-J, et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin. 2019;69(4):305–43.
5. Rangaraju S, Farago A, Heym KM, et al. Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions [abstract no.P14.19]. Neuro Oncol. 2017;19(Suppl 3):iii106.
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献